Multiple Sclerosis Journal · 2017 · 10 citations · 7 references
Life SciencesNeurologyNeuroscienceImmunotherapyMonoclonal AntibodiesNeuroimmunologyAutoimmune Neurological DisordersCentral Nervous System ImmunityCentral Nervous System InfectionsEncephalitisMultiple SclerosisMultiple Sclerosis PharmacotherapyAdhesion Molecule DownregulationHumanized Monoclonal AntibodiesImmune Cell MigrationImmune-mediated DemyelinationInflammatory DemyelinationIntegrin AntagonistsMeningitis RiskMultiple Sclerosis Therapy
Natalizumab is a recombinant humanized monoclonal antibody that decreases T-cell migration into the central nervous system (CNS) through α4 integrin:adhesion-molecule inhibition, thereby increasing the risk for opportunistic CNS infection. Herein, we report a case of infusion-associated aseptic meningitis in a patient receiving natalizumab.
7
A method for estimating the probability of adverse drug reactions
C. A. Naranjo, U. Busto, Edward M. Sellers et al. · Clinical Pharmacology & Therapeutics · 1981 · 11.6K citations